LEAP THERAPEUTICS, INC.

LEAP THERAPEUTICS, INC. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. This stock has a reasonable momentum. LEAP THERAPEUTICS, INC. is not a good value stock. LEAP THERAPEUTICS, INC. is a mediocre stock to choose.
Log in to see more information.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company. It invests in great science a...
LPTX Fundamental Data by TradingView

News

Leap Therapeutics Reports Second Quarter 2024 Financial Results
Leap Therapeutics Reports Second Quarter 2024 Financial Results

PR Newswire Leap Therapeutics Reports Second Quarter 2024 Financial Results Leap Therapeutics Reports Second Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Aug. 12, 2024 CAMBRIDGE, Mass., Aug. 12...\n more…

Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics Reports First Quarter 2024 Financial Results

PR Newswire Leap Therapeutics Reports First Quarter 2024 Financial Results Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., May 13, 2024 CAMBRIDGE, Mass., May 13, 2024...\n more…

Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics Announces $40 Million Private Placement

PR Newswire Leap Therapeutics Announces $40 Million Private Placement Leap Therapeutics Announces $40 Million Private Placement PR Newswire CAMBRIDGE, Mass., April 11, 2024 Net proceeds, along with existing...\n more…

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

PR Newswire Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass., March 18...\n more…

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

PR Newswire Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe...\n more…

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE...\n more…